SKINW / Beauty Health Company (The) - Warrants (04/05/2026) - Dosare SEC, Raport anual, Declarație de procură

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 SkinHealth Systems Inc. (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporat

SEVERANCE AND GENERAL RELEASE AGREEMENT

SEVERANCE AND GENERAL RELEASE AGREEMENT This Severance and General Release Agreement ("Agreement"), made this 6th day of May 2026, by and between Ron Menezes, an individual (“Employee”), and Hydrafacial LLC, a California limited liability company, and SkinHealth Systems Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2026 SkinHealth Systems In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2026 SkinHealth Systems Inc. (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 SkinHealth Systems In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 SkinHealth Systems In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 SkinHealth Systems Inc. (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission Fil

SkinHealth Systems Reports First Quarter 2026 Financial Results

Exhibit 99.1 SkinHealth Systems Reports First Quarter 2026 Financial Results Long Beach, Calif., May 7, 2026 – SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2026 (“Q1 2026”). “First quarter results reflect the strength of the business. We delivered revenue w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 SkinHealth Systems In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 SkinHealth Systems Inc. (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission Fil

ANNUAL REPORT

2025 Annual Report to Stockholders *#)
())( (*')(
#
-#
$""(($# ,1B89=7C>=

 $'"
  ##*!
'%$')
%*'(*#)
)$
()$#

$'
4
$
)
(*')(
-#
)
$
  >A
C85
69B31;
H51A
5=454
535<25A

 $'  )'#()$#
'%$')
%*'(*#)
)$
()$#

$'
4
$
)
(*' )(
-#
)
$
  ><<9BB9>=
69;5
=D<25A
  )85
51DCH
51;C8
>6
A579BCA1=C
1B
B?5396954
9=
9CB
381AC5A 5;1F1A5    /M:M>
HK
HMA>K
CNKBL=BK
%=>GMB?B<:MBHG
*H 

DA=5CC
(CA55C !>=7
5138
    
  ==K>LL
H?
,KBG
+??B<>L
BG .

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

RESTATED CERTIFICATE OF INCORPORATION SKINHEALTH SYSTEMS INC.

RESTATED CERTIFICATE OF INCORPORATION OF SKINHEALTH SYSTEMS INC. SkinHealth Systems Inc. (formerly known as The Beauty Health Company) (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (as amended from time to time, the “DGCL”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is SkinHealth Systems In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2026 SkinHealth Systems

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2026 SkinHealth Systems Inc. (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

SkinHealth Systems Inc. Appoints Three New Independent Directors to Board Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie bring deep expertise in medical devices, aesthetic medicine, and global consumer brands

SkinHealth Systems Inc. Appoints Three New Independent Directors to Board Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie bring deep expertise in medical devices, aesthetic medicine, and global consumer brands Long Beach, CA, April 22, 2026 – SkinHealth Systems Inc. (formerly The Beauty Health Company; Nasdaq: SKIN), a global medical aesthetics company, today announced the appointment

THIRD CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE BEAUTY HEALTH COMPANY (Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

THIRD CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE BEAUTY HEALTH COMPANY (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) The Beauty Health Company (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (as amended from time to time, the “DGCL”) does hereby certify as follows: 1.

The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform The Company will continue trading on the Nasdaq Capital Market under the ticker sym

The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform The Company will continue trading on the Nasdaq Capital Market under the ticker symbol “SKIN” LONG BEACH, Calif.

SECOND AMENDED AND RESTATED BYLAWS SKINHEALTH SYSTEMS INC. ARTICLE I

SECOND AMENDED AND RESTATED BYLAWS OF SKINHEALTH SYSTEMS INC. ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of SkinHealth Systems Inc. (the “Corporation”) within the State of Delaware shall be located at the office of the corporation or individual acting as the Corporation’s registered agent in Delaware, as designated from time to time in the manner provided by law. Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 The Beauty Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39565 The Beauty Health Company (Exact name of registrant as speci

SUBSIDIARIES OF THE BEAUTY HEALTH COMPANY

EXHIBIT 21.1 SUBSIDIARIES OF THE BEAUTY HEALTH COMPANY Name of Subsidiary State or Jurisdiction of Incorporation LCP Edge Intermediate, LLC Delaware Edge Systems Holdings Corporation Delaware Edge Systems Intermediate, LLC Delaware Esthetic Medical Inc. California HydraFacial LLC California The HydraFacial Company Mexico Holdings, LLC Delaware The HydraFacial Company MX, S. de R.L. de C.V. Mexico

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the material terms of the securities of The Beauty Health Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

BeautyHealth Reports Full Year and Fourth Quarter 2025 Financial Results

Exhibit 99.1 BeautyHealth Reports Full Year and Fourth Quarter 2025 Financial Results Long Beach, Calif., March 12, 2026 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the full year and fourth quarter ended December 31, 2025 (“Q4 2025”). "Our fourth quarter results reflects meaningful structura

1 THE BEAUTY HEALTH COMPANY SECOND AMENDED AND RESTATED CLAWBACK POLICY The Beauty Health Company (the “Company”) has adopted this Second Amended and Restated Clawback Policy (this “Policy”), as of March 4, 2026 (the “Second Amendment Effective Date”

exhibit971-secondarclawb 1 THE BEAUTY HEALTH COMPANY SECOND AMENDED AND RESTATED CLAWBACK POLICY The Beauty Health Company (the “Company”) has adopted this Second Amended and Restated Clawback Policy (this “Policy”), as of March 4, 2026 (the “Second Amendment Effective Date”), which policy was originally effective October 2, 2023 (the “Effective Date”).

EXHIBIT C 1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE THE BEAUTY HEALTH COMPANY CONSOLIDATED STOCKHOLDER LITIGATION C.A. No. 2024-0114-LWW NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO: ALL CURRENT RECORD HOLDERS AN

exc-noticeofpendencyexto EXHIBIT C 1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE THE BEAUTY HEALTH COMPANY CONSOLIDATED STOCKHOLDER LITIGATION C.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2026 The Beauty Health C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2026 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 The Beauty Healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commiss

BeautyHealth Reports Third Quarter 2025 Financial Results

Exhibit 99.1 BeautyHealth Reports Third Quarter 2025 Financial Results Long Beach, Calif., November 6, 2025 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the third quarter ended September 30, 2025 (“Q3 2025”). “Our third-quarter results reflect disciplined execution and the continued strengthe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 The Beauty Healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commiss

BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors

BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors LONG BEACH, Calif.

October 10, 2025

October 10, 2025 Marla Beck Via email Re: Separation of Employment Dear Marla: As a follow up to conversations between your representatives and the Company’s representatives, this letter confirms the terms related to the termination without cause of your employment with The Beauty Health Company (the “Company”), which employment was terminated effective September 30, 2025 (the “Separation Date”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of i

GENERAL RELEASE OF ALL CLAIMS

GENERAL RELEASE OF ALL CLAIMS This General Release of all Claims (this “Release”) is entered into on October 10, 2025 by and among The Beauty Health Company (“Parent”), Hydrafacial LLC (the “Company”), and Marla Beck (“Executive”).

US-DOCS\163537025.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of September 29, 2025 and effective as of October 1, 2025 (the “Effective Date”) between The Beauty Health Company (“Parent”), Hydrafacial LLC (the “O

ex101-employmentagreemen US-DOCS\163537025.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of September 29, 2025 and effective as of October 1, 2025 (the “Effective Date”) between The Beauty Health Company (“Parent”), Hydrafacial LLC (the “OpCo” and, together with Parent, the “Company”), and Pedro Malha (“Executive”). WHEREAS, effective as of the Effective Date, t

The Beauty Health Company Names Pedro Malha President and Chief Executive Officer Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared

The Beauty Health Company Names Pedro Malha President and Chief Executive Officer Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth LONG BEACH, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2025 The Beauty Hea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 The Beauty Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

SUPPLEMENTAL INDENTURE NO. 1

Exhibit 4.1 SUPPLEMENTAL INDENTURE NO. 1 SUPPLEMENTAL INDENTURE NO. 1 (this “Supplemental Indenture”), dated as of September 4, 2025, by and among The Beauty Health Company, a Delaware corporation (the “Company”), the existing guarantors party hereto (the “Existing Guarantors”), the entities listed on Schedule I hereto (each a “Guaranteeing Subsidiary”) and U.S. Bank Trust Company, National Associ

BeautyHealth Reports Second Quarter 2025 Financial Results Raises guidance on strong execution and disciplined cost management Advances science-backed innovation with successful launch of the HydraFillic with Pep9™ Booster

Exhibit 99.1 BeautyHealth Reports Second Quarter 2025 Financial Results Raises guidance on strong execution and disciplined cost management Advances science-backed innovation with successful launch of the HydraFillic with Pep9™ Booster Long Beach, Calif., August 7, 2025 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 The Beauty Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

Indenture, dated May 27, 2025, between The Beauty Health Company, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee and collateral agent

EXECUTION VERSION THE BEAUTY HEALTH COMPANY and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee and Collateral Agent INDENTURE Dated as of May 27, 2025 7.95% Convertible Senior Secured Notes due 2028 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 27 Section 1.03. Interpretation 27 Section 1.04. Accounting

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health Comp

Certificate of Correction to Second Amended and Restated Certificate of Incorporation of The Beauty Health Company

STATE OF DELAWARE CERTIFICATE OF CORRECTION TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE BEAUTY HEALTH COMPANY The Beauty Health Company, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”).

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

Indenture, dated May 27, 2025, between The Beauty Health Company, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee and collateral agent

Exhibit 4.1 THE BEAUTY HEALTH COMPANY and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee and Collateral Agent INDENTURE Dated as of May 27, 2025 7.95% Convertible Senior Secured Notes due 2028 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 22 Section 1.03. Interpretation 23 Section 1.04. Accounting Terms

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 The Beauty Health Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

The BeautyHealth Company Announces Convertible Debt Refinancing Refinancing extends maturity of existing debt and strengthens Company’s financial position to advance growth strategy

Exhibit 99.1 The BeautyHealth Company Announces Convertible Debt Refinancing Refinancing extends maturity of existing debt and strengthens Company’s financial position to advance growth strategy LONG BEACH, Calif.-(GLOBE NEWSWIRE)—May 21, 2025 – The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced that it entered into privately negotiated exchange agreement

Form of Exchange Agreement

Exhibit 10.1 The Beauty Health Company [FORM OF] Exchange Agreement May 21, 2025 Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 4 Section 3. The Exchange 5 (a) Generally 5 (b) The Closing 5 Section 4. Representations, Warranties and Covenants of the Company and the Guarantors 7 (a) Due Formation, Valid Existence and Good Standing; Power to Perform Obligations 7 (b

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health Com

BeautyHealth Reports First Quarter 2025 Financial Results

Exhibit 99.1 BeautyHealth Reports First Quarter 2025 Financial Results Long Beach, Calif., May 8, 2025 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”). “Our first quarter results reflect strong execution and continued momentum in our transformat

FORM ARS

2024 Annual Report to Stockholders *#)
())( (*')(
#
-#
$""(($# ,1B89=7C>=

 $'"
  ##*!
'%$')
%*'(*#)
)$
()$#

$'
4
$
)
(*')(
-#
)
$
  >A
C85
69B31;
H51A
5=454
535<25A

 $'  )'#()$#
'%$')
%*'(*#)
)$
()$#

$'
4
$
)
(*' )(
-#
)
$
  ><<9BB9>=
69;5
=D<25A
  )85
51DCH
51;C8
>6
A579BCA1=C
1B
B?5396954
9=
9CB
381AC5A 5;1F1A5    .

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

Insider Trading Policy

Effective May 4, 2021 THE BEAUTY HEALTH COMPANY INSIDER TRADING POLICY PURPOSE This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of The Beauty Health Company (the “Company”) and the handling of confidential information about the Company and its subsidiaries and the companies with which the Company and its subsidiaries do business.

Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the material terms of the securities of The Beauty Health Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Subsidiaries of The Beauty Health Company

EXHIBIT 21.1 SUBSIDIARIES OF THE BEAUTY HEALTH COMPANY Name of Subsidiary State or Jurisdiction of Incorporation LCP Edge Intermediate, LLC Delaware Edge Systems Holdings Corporation Delaware Edge Systems Intermediate, LLC Delaware Esthetic Medical Inc. California HydraFacial LLC California The HydraFacial Company Mexico Holdings, LLC Delaware The HydraFacial Company MX, S. de R.L. de C.V. Mexico

BeautyHealth Reports Full Year and Fourth Quarter 2024 Financial Results Delivers fourth quarter and full year net sales of $83.5 million and $334.3 million

Exhibit 99.1 BeautyHealth Reports Full Year and Fourth Quarter 2024 Financial Results Delivers fourth quarter and full year net sales of $83.5 million and $334.3 million Long Beach, Calif., March 12, 2025 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth”), home to flagship brand Hydrafacial, today announced financial results for the fourth quarter ended December 31, 2024 (“Q4 2024”). “In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39565 The Beauty Health Company (Exact name of registrant as speci

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

Offer Letter with Ronald Menezes, dated October 9, 2024

CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED October 9, 2024 Ron Menezes [*****] Dear Ron, We are excited to extend you an offer to join Hydrafacial LLC, a BeautyHealth Company, as our Chief Revenue Officer.

Offer Letter with Sheri Lewis, dated March 25, 2024

CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED March 25, 2024 Sheri Lewis [*****] Dear Sheri, We are excited to extend you an offer to join Hydrafacial LLC, a BeautyHealth Company, as our Chief Supply Chain and Operations Officer.

BEAUTYHEALTH NAMES SHERI LEWIS AS CHIEF SUPPLY CHAIN AND OPERATIONS OFFICER

BEAUTYHEALTH NAMES SHERI LEWIS AS CHIEF SUPPLY CHAIN AND OPERATIONS OFFICER LONG BEACH, Calif.

The Beauty Health Company Strengthens Commercial Leadership Team with Chief Revenue Officer and Chief Marketing Officer Appointments

The Beauty Health Company Strengthens Commercial Leadership Team with Chief Revenue Officer and Chief Marketing Officer Appointments LONG BEACH, Calif.

BeautyHealth Appoints Stephen J. Fanning to Board of Directors Medical Aesthetics Veteran Brings Extensive Industry Knowledge and Proven Success in Driving Global Growth

EX-99.1 2 exhibit991-beautyhealthsfb.htm EX-99.1 BeautyHealth Appoints Stephen J. Fanning to Board of Directors Medical Aesthetics Veteran Brings Extensive Industry Knowledge and Proven Success in Driving Global Growth LONG BEACH, Calif.-(BUSINESS WIRE)—December 17, 2024 - The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment of medical aesthe

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

SKIN / The Beauty Health Company / Divisadero Street Capital Management, LP Passive Investment

SC 13G/A 1 d1152808913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* The Beauty Health Company (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 88331L108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch

SKIN / The Beauty Health Company / JANUS HENDERSON GROUP PLC - JANUS AMENDMENT Passive Investment

SC 13G/A 1 Beauty093024.txt JANUS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 4* Name of Issuer: The Beauty Health Company Title of Class of Securities: Class A Common Stock CUSIP Number: 88331L108 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to

SKIN / The Beauty Health Company / Luxor Capital Partners, Lp Passive Investment

SC 13G/A 1 beauty13ga3-11142024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 3)* The Beauty Health Company (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 88

BeautyHealth Reports Third Quarter 2024 Financial Results Delivers third quarter net sales of $78.8 million; Delivers improved profitability as strategic initiatives start to take hold Successfully launches Hydralock HA Booster

Exhibit 99.1 BeautyHealth Reports Third Quarter 2024 Financial Results Delivers third quarter net sales of $78.8 million; Delivers improved profitability as strategic initiatives start to take hold Successfully launches Hydralock HA Booster Long Beach, Calif., November 12, 2024 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth”), home to flagship brand Hydrafacial, today announced financia

SKIN / The Beauty Health Company / VANGUARD GROUP INC Passive Investment

SC 13G/A 1 UnitedStates13GBeautyHeal.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* (Name of Issuer) Beauty Health Co/The (Title of Class of Secu

Separation and Transition Agreement, dated November 11, 2024, by and between Hydrafacial LLC and Daniel Watson

CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SEPARATION AND TRANSITION AGREEMENT This Separation and Transition Agreement (“Agreement”) is made and entered into as of November 11, 2024 (the “Signing Date”), but for all purposes shall be effective as of October 14, 2024 (the “Effective Date”), by and between Daniel Watson, an individual (“Employee”), and Hydrafacial LLC, a California corporation (the "Company") (together, the "Parties"), is a severance agreement which includes a general release of claims.

SKIN / The Beauty Health Company / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.7 BEAUTY HEALTH CO/THE CLASS A COMMON STOCK Cusip #88331L108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #88331L108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 18,603,037 Item 6: 0 Item 7: 18,603,037 Item 8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 The Beauty Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health

SKIN / The Beauty Health Company / VANGUARD GROUP INC Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* (Name of Issuer) Beauty Health Co/The (Title of Class of Securities) Common Stock (CUSIP Number) 88331

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissi

BeautyHealth Reports Second Quarter 2024 Financial Results Delivers second quarter net sales of $90.6 million; Year-over-year operating expense improvement of nearly $18 million or 22%; Revises full year financial guidance

Exhibit 99.1 BeautyHealth Reports Second Quarter 2024 Financial Results Delivers second quarter net sales of $90.6 million; Year-over-year operating expense improvement of nearly $18 million or 22%; Revises full year financial guidance Long Beach, Calif., August 8, 2024 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth”), home to flagship brand Hydrafacial, today announced financial result

Bonus Opportunity Letter, dated August 6, 2024, for Michael Monahan

USACTIVE-181295609.1 August 6, 2024 Mike Monahan 3600 E. Burnett St. Long Beach, CA 90815 Re: Cash-Based Performance Bonus Opportunity Dear Mike: The Beauty Health Company and HydraFacial LLC (together with any of their respective successors or assigns, the “Company”), wish to provide you with the following cash-based performance award opportunity under the terms and on the conditions outlined bel

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health Comp

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of The Beauty Health Company

CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE BEAUTY HEALTH COMPANY (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) The Beauty Health Company (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (as amended from time to time, the “DGCL”), does hereby certify as follows: 1.

Second Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of The Beauty Health Company

SECOND CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE BEAUTY HEALTH COMPANY (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) The Beauty Health Company (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (as amended from time to time, the “DGCL”), does hereby certify as follows: 1.

SKIN / The Beauty Health Company / Divisadero Street Capital Management, LP Passive Investment

SC 13G 1 d1105249613-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* The Beauty Health Company (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 88331L108 (CUSIP Number) May 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the app

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission F

BeautyHealth Reports First Quarter 2024 Financial Results Delivers first quarter net sales of $81.4 million; year-over-year operating expense improvement of $6.1 million Repurchases $192.3 million of convertible notes through May 8th

Exhibit 99.1 BeautyHealth Reports First Quarter 2024 Financial Results Delivers first quarter net sales of $81.4 million; year-over-year operating expense improvement of $6.1 million Repurchases $192.3 million of convertible notes through May 8th Long Beach, Calif., May 9, 2024 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth”), home to flagship brand Hydrafacial, today announced financia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health Com

, by and between The Beauty Health Company and Goldman Sachs & Co. LLC

\\\DC - 71532/300 - #1291878 v5 PURCHASE AGREEMENT Purchase Agreement, dated April 1, 2024 (the “Purchase Agreement”), between The Beauty Health Company (the “Purchaser”) and Goldman Sachs & Co.

ween The Beauty Health Company and Goldman Sachs & Co. LLC

\\\DC - 71532/300 - #1291878 v5 PURCHASE AGREEMENT Purchase Agreement, dated December 15, 2023 (the “Purchase Agreement”), between The Beauty Health Company (the “Purchaser”) and Goldman Sachs & Co.

Separation, Transition and General Release Agreement, dated April 29, 2024, by and between Hydrafacial LLC and Brad Hauser

CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SEPARATION, TRANSITION AND GENERAL RELEASE AGREEMENT This Separation, Transition and General Release Agreement (“Agreement”) made this 26th day of April 2024 (the “Effective Date”), by and between Brad Hauser, an individual (“Employee”), and Hydrafacial LLC, a California limited liability company (the "Company") (together, the "Parties"), is a separation agreement which includes a general release of claims.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

ANNUAL REPORT

2023 Annual Report to Stockholders)"(
'((' ')&('
"
,"
#!!''#" +0B78=6C>=

  #&!

 "")
&$#&(
$)&')"(
(#
'(#"

#&
3
#
(
')&('
,"
(
#
 >A
C74
58B20;
H40A
4=343
424<14A

#&  (&"'(#"
&$#&(
$)&')"(
(#
'(#"

#&
3
#
(
')& ('
,"
(
#
 ><<8BB8>=
58;4
=D<14A
 
(74
40DCH
40;C7
>5
A468BCA0=C
0B
B?4285843
8=
8CB
270AC4A 4;0F0A4    /M:M>
HK
HMA>K
CNKBL=BK
%=>GMB?B<:MBHG
*H 
'?A8=6
'CA44C >=6
4027

  
    ==K>LL
H?
,KBG
+??B<>L
BG .

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 The Beauty Health C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

Employment Agreement, dated April 8, 2024, by and among The Beauty Health Company, HydraFacial LLC, and Marla Beck

Marla Beck CEO Employment Agreement 1 ACTIVE/128259303.13 CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of April 8, 2024, and effective as of April 8, 2024 (the “Effect

The Beauty Health Company Amended and Restated Executive Severance Plan

US-DOCS\148350726.5 THE BEAUTY HEALTH COMPANY AMENDED AND RESTATED EXECUTIVE SEVERANCE PLAN The Beauty Health Company (the “Company”), has adopted this The Beauty Health Company Amended and Restated Executive Severance Plan, including the attached Exhibits (the “Plan”), effective as of April 5, 2024 (the “Effective Date”), for the benefit of Participants (as defined below) on the terms and conditi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 The Beauty Health C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

SKIN / The Beauty Health Company / JANUS HENDERSON GROUP PLC - JHG PLC OWNS 10% Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 3* Name of Issuer: The Beauty Health Company Title of Class of Securities: Class A Common Stock CUSIP Number: 88331L108 Date of Event Which Requires Filing of this Statement: 3/31/2024 Check the appropriate box to designate the rule pursuant to which this Sc

SKIN / The Beauty Health Company / LCP Edge Holdco LLC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)* The Beauty Health Company (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 88331L 108 (CUSIP Number) LCP Edge H

BeautyHealth Announces Appointment Of Marla Beck As Chief Executive Officer

BeautyHealth Announces Appointment Of Marla Beck As Chief Executive Officer LONG BEACH, Calif.

BeautyHealth Reports Full Year and Fourth Quarter 2023 Financial Results Delivers net sales of $398 million for the full year and $96.8 million for the fourth quarter driven by growth across international markets

Exhibit 99.1 BeautyHealth Reports Full Year and Fourth Quarter 2023 Financial Results Delivers net sales of $398 million for the full year and $96.8 million for the fourth quarter driven by growth across international markets Long Beach, Calif., March 12, 2024 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth”), home to flagship brand Hydrafacial, today announced financial results for the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

Subsidiaries of The Beauty Health Company

EXHIBIT 21.1 SUBSIDIARIES OF THE BEAUTY HEALTH COMPANY Name of Subsidiary State or Jurisdiction of Incorporation LCP Edge Intermediate, LLC Delaware Edge Systems Holdings Corporation Delaware Edge Systems Intermediate, LLC Delaware Esthetic Medical Inc. Arizona HydraFacial LLC California The HydraFacial Company Mexico Holdings, LLC Delaware The HydraFacial Company MX, S. de R.L. de C.V. Mexico The

he Beauty Health Company Amended and Restated Clawback Policy

1 US-DOCS\143410591.3 THE BEAUTY HEALTH COMPANY AMENDED AND RESTATED CLAWBACK POLICY The Beauty Health Company (the “Company”) has adopted this Amended and Restated Clawback Policy (this “Policy”), effective as of October 2, 2023 (the “Effective Date”). This Policy amends, restates and supersedes in its entirety the Company’s Clawback Policy, which was originally adopted by the Company on May 4, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39565 The Beauty Health Company (Exact name of registrant as speci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 The Beauty Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

SKIN / The Beauty Health Company / Luxor Capital Group, LP Passive Investment

SC 13G/A 1 beauty13ga2-02142024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* The Beauty Health Company (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 88

SKIN / The Beauty Health Company / JANUS HENDERSON GROUP PLC - JHG PLC OWNS >5% Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: The Beauty Health Company Title of Class of Securities: Class A Common Stock CUSIP Number: 88331L108 Date of Event Which Requires Filing of this Statement: 12/31/2023 Check the appropriate box to designate the rule pursuant to which this S

SKIN / The Beauty Health Company / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0416-beautyhealthcompanycl.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Beauty Health Company Class A Title of Class of Securities: Common Stock CUSIP Number: 88331L108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate

SKIN / The Beauty Health Company / Senvest Management, LLC - THE BEAUTY HEALTH COMPANY Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* The Beauty Health Company (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 88331L108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

SKIN / The Beauty Health Company / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 BEAUTY HEALTH CO/THE CLASS A COMMON STOCK Cusip #88331L108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #88331L108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 16,779,475 Item 6: 0 Item 7: 16,786,185 Item 8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of in

, dated December 8, 2023, by and between The Beauty Health Company and

CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED December 8, 2023 Andrew Stanleick Via email Re: Separation of Employment Dear Andrew: As a follow up to our conversations, this letter confirms the terms related to the Company’s exercise of its option to terminate your employment without cause.

SKIN / Beauty Health Company (The) - Class A / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.5 BEAUTY HEALTH CO/THE CLASS A COMMON STOCK Cusip #88331L108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #88331L108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,689,017 Item 6: 0 Item 7: 12,693,892 Item 8: 0 Item 9: 12,693,892

Form of Restricted Stock Unit Agreement

THE BEAUTY HEALTH COMPANY 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE The Beauty Health Company, a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of The Beauty Health Company 2021 Incentive Award Plan (as amended from time to time, the “Plan”) and the Restricted Stock Unit Agreement attached hereto as Exhibit A (the “Agreement”), both of which are incorporated into this Grant Notice by reference.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 The Beauty Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health

, dated November 13, 2023, by and between The Beauty Health Company and

USACTIVE-175944529.6 November 12, 2023 Via Email Marla Beck Re: Offer Letter As Interim CEO of The Beauty Health Company Dear Ms. Beck: We are pleased to extend you an offer of employment with The Beauty Health Company (the “Company”) as its interim Chief Executive Officer under the terms provided in this offer letter. The term of your employment as interim CEO shall be six (6) months (the “Term”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 The Beauty Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

BeautyHealth Reports Third Quarter 2023 Financial Results Revises financial guidance on lower-than-expected U.S. revenue and incurs restructuring charges for device upgrades Delivers net sales of $97.4 million driven by double digit growth in APAC an

Exhibit 99.1 BeautyHealth Reports Third Quarter 2023 Financial Results Revises financial guidance on lower-than-expected U.S. revenue and incurs restructuring charges for device upgrades Delivers net sales of $97.4 million driven by double digit growth in APAC and EMEA Long Beach, Calif., November 13, 2023 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 The Beauty Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

1 BeautyHealth Announces Leadership Transition Beauty Industry Veteran and BeautyHealth Director Marla Beck to Serve as Interim CEO, Succeeding Andrew Stanleick Long Beach, Calif., November 13, 2023—The BeautyHealth Company (NASDAQ: SKIN), home to fl

1 BeautyHealth Announces Leadership Transition Beauty Industry Veteran and BeautyHealth Director Marla Beck to Serve as Interim CEO, Succeeding Andrew Stanleick Long Beach, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

SKIN / Beauty Health Company (The) - Class A / JANUS HENDERSON GROUP PLC - JHG PLC OWNS 10.1% Passive Investment

SC 13G/A 1 beauty103123.txt JHG PLC OWNS 10.1% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: The Beauty Health Company Title of Class of Securities: Class A Common Stock CUSIP Number: 88331L108 Date of Event Which Requires Filing of this Statement: 10/31/2023 Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 The Beauty Hea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commi

BeautyHealth Announces Business Transformation Program to Drive Profitability and Growth; Board of Directors Authorizes $100 Million Share Repurchase Sep 12, 2023 First phase of the transformation program expected to generate over $20 million annuali

BeautyHealth Announces Business Transformation Program to Drive Profitability and Growth; Board of Directors Authorizes $100 Million Share Repurchase Sep 12, 2023 First phase of the transformation program expected to generate over $20 million annualized cost savings during Q1 2024; second phase expected to generate over $15 million annualized cost savings during Q2 2024 Company re-affirms long-term 2025 financial guidance of $600 to $700 million net sales, up to 500 basis points gross margin expansion vs.

, dated August 10, 2023, by and between The Beauty Health Company and Liyuan Woo

CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED August 3, 2023 Liyuan Woo Via email Re: Separation of Employment Dear Liyuan: As a follow up to our conversations, this letter confirms the terms related to the Company’s exercise of its option to terminate your employment without cause.

BeautyHealth Reports Second Quarter 2023 Financial Results Delivers double-digit net sales growth on demand for Hydrafacial Confirms 2023 net sales and 2025 financial guidance, refines 2023 adjusted EBITDA margin guidance

Exhibit 99.1 BeautyHealth Reports Second Quarter 2023 Financial Results Delivers double-digit net sales growth on demand for Hydrafacial Confirms 2023 net sales and 2025 financial guidance, refines 2023 adjusted EBITDA margin guidance Long Beach, Calif., August 9, 2023 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced financial results for the second q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 The Beauty Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health Comp

BeautyHealth Names Michael Monahan Chief Financial Officer

BeautyHealth Names Michael Monahan Chief Financial Officer LONG BEACH, Calif. – August 9, 2023 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announces Michael Monahan has been named Chief Financial Officer, effective August 10, 2023. He succeeds Liyuan Woo, who is leaving BeautyHealth but will remain as an advisor until September 1, 2023 to assist with the t

Employment Agreement, dated August 10, 2023, by and among The Beauty Health Company, HydraFacial LLC, and Michael Monahan

EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of August 7, 2023 and effective as of August 10, 2023 (the “Effective Date”) between The Beauty Health Company (“Parent”), Hydrafacial LLC (the “OpCo” and, together with Parent, the “Company”), and Michael Monahan (“Executive”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 The Beauty Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

SKIN / Beauty Health Company (The) - Class A / LCP Edge Holdco LLC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)* The Beauty Health Company (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 88331L 108 (CUSIP Number) LCP Edge H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 The Beauty Health C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be

SKIN / Beauty Health Company (The) - Class A / Senvest Management, LLC - THE BEAUTY HEALTH COMPANY Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* The Beauty Health Company (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 88331L108 (CUSIP Number) May 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The Beauty Health Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 The Beauty Health Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

BeautyHealth Reports First Quarter 2023 Financial Results On strong consumer demand, delivers double-digit net sales growth in line with 2023 plan Raises fiscal 2023 net sales guidance

Exhibit 99.1 BeautyHealth Reports First Quarter 2023 Financial Results On strong consumer demand, delivers double-digit net sales growth in line with 2023 plan Raises fiscal 2023 net sales guidance Long Beach, Calif., May 10, 2023 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2023. For the qua

Hydrafacial is upping its cool factor, one brand partnership at a time The Hydrafacial Phenomenon: Why Everyone Is Obsessed With This In-Office Treatment“ ” “ ”

a20231qearningsdeckvf Hydrafacial is upping its cool factor, one brand partnership at a time The Hydrafacial Phenomenon: Why Everyone Is Obsessed With This In-Office Treatment“ ” “ ”

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39565 The Beauty Health Company (Exact name of registrant as speci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Maturing into a Multi-Brand Ecosystem, BeautyHealth Appoints Aesthetics Veteran Brad Hauser as Chief Operating Officer Newly created role establishes end-to-end product oversight, from innovation to go-to-market

Exhibit 99.1 Maturing into a Multi-Brand Ecosystem, BeautyHealth Appoints Aesthetics Veteran Brad Hauser as Chief Operating Officer Newly created role establishes end-to-end product oversight, from innovation to go-to-market LONG BEACH, Calif.— April 19, 2023 —The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced Brad Hauser’s promotion to Chief Operating Of

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

Promotion Offer Letter with Brad Hauser, dated April 7, 2023

Exhibit 10.1 April 7, 2023 Dear Brad, Congratulations on your promotion to your new role as Chief Operating Officer! In this role you will continue to report directly to me and will remain a member of the executive committee. Based on your promotion, the Board of Directors has approved your new annual salary of $475,000. This amount, less applicable withholdings and deductions will be effective Ap

First Amendment to The Beauty Health Company Executive Severance Plan

Exhibit 10.1 FIRST AMENDMENT TO THE BEAUTY HEALTH COMPANY EXECUTIVE SEVERANCE PLAN This First Amendment (this “First Amendment”) to The Beauty Health Company Executive Severance Plan (the “Plan”) is made and adopted by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of The Beauty Health Company, a Delaware corporation (the “Company”), effective as of February 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 THE BEAUTY HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 THE BEAUTY HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

Subsidiaries of registrant

EXHIBIT 21.1 SUBSIDIARIES OF THE BEAUTY HEALTH COMPANY Name of Subsidiary State or Jurisdiction of Incorporation LCP Edge Intermediate, LLC Delaware Edge Systems Holdings Corporation Delaware Edge Systems Intermediate, LLC Delaware HydraFacial LLC California The Personalized Beauty Company, Inc. Delaware The HydraFacial Company MX, S. de R.L. de C.V. Mexico The HydraFacial Company Mexico Holdings,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39565 The Beauty Health Company (Exact name of registrant as speci

Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.4 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the material terms of the securities of The Beauty Health Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This description of the terms of our stock does not purport to be a complete s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 THE BEAUTY HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

BeautyHealth Reports Full Year and Fourth Quarter 2022 Financial Results

Exhibit 99.1 BeautyHealth Reports Full Year and Fourth Quarter 2022 Financial Results •Delivers +41% year-over-year topline growth for the year and exceeds market expectations for eighth consecutive quarter •Increases adjusted EBITDA +46% year-over-year, landing within guided annual range •Sets 2023 profitable growth targets on strategy to increase operating leverage and accelerate in China, confi

Jan-19 Jul-19 Jan-20 Jun-20 Dec-20 Jun-21 Dec-21 Jun-22 Dec-22 Interest over time 2021 average I discovered the Hydrafacial when I was working in France. I really saw the difference. My skin has never felt so clean and glowing. • •

a20224qearningspresentat Jan-19 Jul-19 Jan-20 Jun-20 Dec-20 Jun-21 Dec-21 Jun-22 Dec-22 Interest over time 2021 average I discovered the Hydrafacial when I was working in France. I really saw the difference. My skin has never felt so clean and glowing. • •

BeautyHealth to Acquire SkinStylus®, FDA-Cleared Microneedling Device Acquisition is a strategic step in portfolio build-up and BeautyHealth long-term vision

Exhibit 99.1 BeautyHealth to Acquire SkinStylus®, FDA-Cleared Microneedling Device Acquisition is a strategic step in portfolio build-up and BeautyHealth long-term vision Long Beach, Calif., February 28, 2023 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand HydrafacialTM, today announced a definitive agreement to acquire SkinStylus®, an FDA-cleared microneedling device. The agree

Stock Purchase Agreement by and among Dr. Lawrence Groop, Kristin Groop, Esthetic Education, LLC, and Edge Systems Intermediate, LLC, dated as of February 27, 2023

CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED STOCK PURCHASE AGREEMENT among DR.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 THE BEAUTY HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

SKIN / The Beauty Health Company Class A / Luxor Capital Group, LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* The Beauty Health Company (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 88331L108 (CUSIP Number) December 31,

SKIN / The Beauty Health Company Class A / JANUS HENDERSON GROUP PLC - JHG PLC OWNS >5% Passive Investment

SC 13G 1 beauty02132023.txt JHG PLC OWNS >5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: The Beauty Health Company Title of Class of Securities: Class A Common Stock CUSIP Number: 88331L108 Date of Event Which Requires Filing of this Statement: 12/31/2022 Check the appropriate box t

SKIN / The Beauty Health Company Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0390-beautyhealthco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Beauty Health Co. Title of Class of Securities: Common Stock CUSIP Number: 88331L108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate th

SKIN / The Beauty Health Company Class A / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.4 BEAUTY HEALTH CO/THE CLASS A COMMON STOCK Cusip #88331L108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #88331L108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 22,632,685 Item 6: 0 Item 7: 22,632,685 Item 8: 0 Item 9: 22,632,685

THE BEAUTY HEALTH COMPANY 68,433,360 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed pursuant to Rule 424(b)(3) Registration No. 333-257995 Registration No. 333-267051 THE BEAUTY HEALTH COMPANY 68,433,360 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus relates to the resale from time to time of (i) an aggregate of 68,433,360 shares of Class A common stock

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissi

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No. 3 to Form S-1 on Form S-3 (Form Type) The Beauty Health Company (Exact Name of Registrant as Specified in its Charter) Table3: Combined Prospectuses Security Type Security Class Title Amount of Securities Previously Registered(1) Maximum Aggregate Offering Price of Securities Previously Registered Form Type File Number Initi

As filed with the Securities and Exchange Commission on December 30, 2022

As filed with the Securities and Exchange Commission on December 30, 2022 Registration No.

LETTER

United States securities and exchange commission logo December 22, 2022 Liyuan Woo Chief Financial Officer Beauty Health Co 2165 Spring Street Long Beach, CA 90806 Re: Form 10-K filed March 1, 2022 File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 The Beauty Health Company (Exact name of

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 13 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission Fi

* * * *

December 15, 2022 Via EDGAR Transmission Division of Corporation Finance Office of Industrial Applications and Services U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File N

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 14 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 15 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Nu

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 16 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement

LETTER

United States securities and exchange commission logo December 5, 2022 Liyuan Woo Chief Financial Officer Beauty Health Co 2165 Spring Street Long Beach, CA 90806 Re: Form 10-K filed March 1, 2022 File No.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commis

Amended and Restated Credit Agreement, dated as of November 14, 2022, among The Beauty Health Company, a Delaware corporation (as successor by assumption to HydraFacial LLC (formerly known as Edge Systems LLC), a California limited liability company), as borrower, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.1 EXECUTION VERSION AMENDED AND RESTATED CREDIT AGREEMENT dated as of November 14, 2022 among THE BEAUTY HEALTH COMPANY (as successor by assumption to HydraFacial LLC), as Borrower The Other Loan Parties Party Hereto The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent, JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger TABLE OF CONTENTS Page

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 12 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information co

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 11 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information co

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commiss

BeautyHealth Enters into $100 Million Accelerated Share Repurchase Agreement

Exhibit 99.1 BeautyHealth Enters into $100 Million Accelerated Share Repurchase Agreement Long Beach, Calif., November 10, 2022 ? The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced that it has entered into an accelerated share repurchase agreement (?ASR?) with JP Morgan Chase Bank, N.A., to repurchase an additional $100 million of the Company?s common sto

Separation Agreement, dated as of August 3, 2022, between Hydrafacial LLC and Indra Pamamull

Exhibit 10.2 CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SEPARATION AGREEMENT This agreement (?Separation Agreement?) is entered into as of 3 August 2022 but shall be effective as of 8 June 2022 between: (1)HydraFacial LLC (f/k/a Edge Systems, LL

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 10 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565

BeautyHealth Reports Third Quarter 2022 Financial Results Net sales beat expectations for seventh consecutive quarter Company raises 2022 net sales guidance on continued momentum and strong demand, revises adjusted EBITDA guidance against a complex m

Exhibit 99.1 BeautyHealth Reports Third Quarter 2022 Financial Results Net sales beat expectations for seventh consecutive quarter Company raises 2022 net sales guidance on continued momentum and strong demand, revises adjusted EBITDA guidance against a complex macro backdrop Long Beach, Calif., November 8, 2022 ? The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commiss

° ✓ ✓ ✓ ✓ ✓ ∆ ∆ ∆ Reconciliation of net income to adjusted EBITDA ($mm) Net sales Net income (loss) Adjusted to exclude the following: Change in FV of warrant liability Change in FV of earn-out shares liability Amortization expense Gain / loss on dis

? ? ? ? ? ? ? ? ? Reconciliation of net income to adjusted EBITDA ($mm) Net sales Net income (loss) Adjusted to exclude the following: Change in FV of warrant liability Change in FV of earn-out shares liability Amortization expense Gain / loss on disposal of assets Stock-based compensation expense Other expense (income) Management fees1 Transaction related costs2 Other non-recurring and one-time fees3 Aaaregate adjustment for income taxes Adiusted net income (loss) Depreciation expense Interest expense Foreign currency (gain) loss, net Remaininq benefit for income taxes Adjusted EBITDA Adjusted EBITDA margin Three months ended September 30, 2022 2021 $88:8 $68.

BeautyHealth Announces $200 million Share Repurchase Authorization Enters into $100 million accelerated share repurchase agreement

Exhibit 99.1 BeautyHealth Announces $200 million Share Repurchase Authorization Enters into $100 million accelerated share repurchase agreement Long Beach, Calif., Sep. 27, 2022 ? The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced its Board of Directors has authorized a share repurchase program of up to $200 million of the Company?s outstanding common sto

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 9 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commi

Master Confirmation - Uncollared Accelerated Share Repurchase, dated as of September 27, 2022, between JPMorgan Chase Bank, National Association and The Beauty Health Company

Exhibit 10.1 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY, 10179 September 27, 2022 To: The Beauty Health Company 2165 Spring Street Long Beach, CA 90806 Attention: Liyuan Woo Telephone No.: Email: With a Copy to: Paul Bokota Telephone No.: Email: Re: Master Confirmation?Uncollared Accelerated Share Repurchase This master confirmation (this ?Master Conf

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commi

Analyst & Investor Day September 15, 2022 The road to BeautyHealth Brent Saunders Executive Chairman 2 What makes Hydrafacial attractive? Criteria Leading position in attractive and growing industry P Scientific / brand differentiation P Sustainable

Analyst & Investor Day September 15, 2022 The road to BeautyHealth Brent Saunders Executive Chairman 2 What makes Hydrafacial attractive? Criteria Leading position in attractive and growing industry P Scientific / brand differentiation P Sustainable competitive advantages P Suitable platform to build a leading aesthetics technology company focused on allied healthcare professionals P Long-term gro

A Harbinger of Beauty Industry Resiliency, BeautyHealth Announces Three-Year Plan to Double Sales, At Least Triple Profit Company hosts Analyst and Investor Day in New York City today Expects growth across all channels and geographies, projecting EME

Exhibit 99.1 A Harbinger of Beauty Industry Resiliency, BeautyHealth Announces Three-Year Plan to Double Sales, At Least Triple Profit Company hosts Analyst and Investor Day in New York City today Expects growth across all channels and geographies, projecting EMEA and APAC businesses to overtake Americas by 2025 Long Beach, Calif., September 15, 2022 ? The Beauty Health Company (NASDAQ: SKIN), hom

Filed Pursuant to Rule 424(b)(3) Registration No. 333-267051 PROSPECTUS FOR 65,618 SHARES OF CLASS A COMMON STOCK THE BEAUTY HEALTH COMPANY

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-267051 PROSPECTUS FOR 65,618 SHARES OF CLASS A COMMON STOCK OF THE BEAUTY HEALTH COMPANY This prospectus relates to the resale or other disposition from time to time of up to an aggregate of 65,618 shares of Class A common stock, par value $0.0001 per share (the ?Class A Common Stock?), of The Beauty Health Company by the secu

The Beauty Health Company 2165 Spring Street Long Beach, CA 90806

The Beauty Health Company 2165 Spring Street Long Beach, CA 90806 August 31, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissi

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 8 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

LETTER

United States securities and exchange commission logo August 26, 2022 Liyuan Woo Chief Financial Officer The Beauty Health Company 2165 Spring Street Long Beach, CA 90806 Re: The Beauty Health Company Registration Statement on Form S-3 Filed August 24, 2022 File No.

As filed with the Securities and Exchange Commission on August 24, 2022

Table of Contents As filed with the Securities and Exchange Commission on August 24, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) The Beauty Health Company (Exact Name of Registrant as Specified in its Charter) Table1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The

Retention Agreement, dated May 7, 2022, between Daniel Watson and The Beauty Health Company

Exhibit 10.2 Date: May 5, 2022 Daniel Watson Re: Retention Bonus Dear Dan: As you know, The Beauty Health Company (the ?Company?) desires to have you remain with the Company in your current role. We consider your continued service and dedication to the Company to be critical to our business success. To incentivize you to remain employed with the Company, we are pleased to offer you a retention bon

Separation Agreement, dated as of August 3, 2022, between Hyrdrafacial LLC and Indra Pamamull

Exhibit 10.3 CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SEPARATION AGREEMENT This agreement (?Separation Agreement?) is entered into as of 3 August 2022 but shall be effective as of 8 June 2022 between: (1)HydraFacial LLC (f/k/a Edge Systems, LL

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 7 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

1 Q2 2022 EARNINGS PRESENTATION AUGUST 9, 2022 2 Opening Remarks AGENDA Q2 2022 Results & Outlook Q&A 3 DI SCLAI MER This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations o

1 Q2 2022 EARNINGS PRESENTATION AUGUST 9, 2022 2 Opening Remarks AGENDA Q2 2022 Results & Outlook Q&A 3 DI SCLAI MER This Presentation contains certain forward-looking statements.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

BeautyHealth Reports Record Second Quarter 2022 Financial Results All-time high quarterly net sales of $103.5 million, up +55.7% YoY Company raises net sales guidance and reaffirms adjusted EBITDA outlook for the year Exceptional results driven by ac

Exhibit 99.1 BeautyHealth Reports Record Second Quarter 2022 Financial Results All-time high quarterly net sales of $103.5 million, up +55.7% YoY Company raises net sales guidance and reaffirms adjusted EBITDA outlook for the year Exceptional results driven by acceleration of HydraFacial delivery system placements globally, with segment revenue up +85.4% YoY; healthy consumer interest Long Beach,

SKIN / The Beauty Health Company Class A / Luxor Capital Group, LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* The Beauty Health Company (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 88331L108 (CUSIP Number) July 27, 2022

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 6 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorpo

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 4 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 5 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

1 2 3 • • • • • • • • • 4 5 6 7 8 9 ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ 10 ▪ ▪ ▪ ▪ 11 12 ▪ ✓ ✓ ✓ ▪ 13 ▪ ▪ ▪ ▪ 14 15 16 ▪ ▪ ▪ 17 18 19 20 21 22 ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ 23 24 25 26 27 28

1 2 3 ? ? ? ? ? ? ? ? ? 4 5 6 7 8 9 ? ? ? ? ? ? ? ? 10 ? ? ? ? 11 12 ? ? ? ? ? 13 ? ? ? ? 14 15 16 ? ? ? 17 18 19 20 21 22 ? ? ? ? ? ? ? ? ? ? 23 24 25 26 27 28

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 proxyfiling2022supplement.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

BEAUTYHEALTH APPOINTS BLUEMERCURY FOUNDER MARLA BECK TO BOARD OF DIRECTORS

Exhibit 99.1 BEAUTYHEALTH APPOINTS BLUEMERCURY FOUNDER MARLA BECK TO BOARD OF DIRECTORS LONG BEACH, Calif., June 6, 2022?The Beauty Health Company (NASDAQ:SKIN), the breakthrough category creator at the intersection of traditional beauty and aesthetics with its flagship HydraFacial brand, today announced the appointment of Marla Beck to its Board of Directors. The Bluemercury founder will join the

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

FIRST QUARTER 2022 EARNINGS PRESENTATION May 10, 2022 2 DISCLAIMER This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performanc

FIRST QUARTER 2022 EARNINGS PRESENTATION May 10, 2022 2 DISCLAIMER This Presentation contains certain forward-looking statements.

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated May 5, 2022) THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information con

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

The Beauty Health Company Reports Strong First Quarter 2022 Financial Results Increases 2022 Financial Guidance

Exhibit 99.1 The Beauty Health Company Reports Strong First Quarter 2022 Financial Results Increases 2022 Financial Guidance Long Beach, Calif., May 10, 2022 ? The Beauty Health Company ("BeautyHealth" or the "Company"; NASDAQ:SKIN), the breakthrough category creator at the intersection of traditional beauty and aesthetics, today announced financial results for the first quarter ended March 31, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39565 The

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 THE BEAUTY HEALTH COMPANY 76,040,010 SHARES OF CLASS A COMMON STOCK 6,970,000 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 6,970,000 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus relates to the resale from time to time of (i) an aggregate of 76,040,010 shares of Class A common stock, par value $0.0001 per shar

Table of Contents As filed with the Securities and Exchange Commission on April 29, 2022 Registration No. 333-257995 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATE

Table of Contents As filed with the Securities and Exchange Commission on April 29, 2022 Registration No.

• • • • • • • • • ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪

? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commissio

The Beauty Health Company Introduces New Digitally Connected HydraFacial Syndeo™ Delivery System Launch Represents a Significant Technology Upgrade from Existing HydraFacial Delivery System, with Data Collection Capabilities for a Personalized and Co

Exhibit 99.1 The Beauty Health Company Introduces New Digitally Connected HydraFacial Syndeo? Delivery System Launch Represents a Significant Technology Upgrade from Existing HydraFacial Delivery System, with Data Collection Capabilities for a Personalized and Connected Experience Long Beach, Calif., ? March 7, 2022- The Beauty Health Company (?BeautyHealth? or the ?Company?; NASDAQ:SKIN), a globa

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 THE BEAUTY HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission

THE BEAUTY HEALTH COMPANY 89,501,743 SHARES OF CLASS A COMMON STOCK 9,333,333 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 24,666,666 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 13 (to prospectus dated July 26, 2021) THE BEAUTY HEALTH COMPANY 89,501,743 SHARES OF CLASS A COMMON STOCK 9,333,333 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 24,666,666 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to update and supplement the information

THE BEAUTY HEALTH COMPANY 89,501,743 SHARES OF CLASS A COMMON STOCK 9,333,333 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 24,666,666 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS

424B3 1 a424b3-fy2110xk.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-257995 PROSPECTUS SUPPLEMENT NO. 12 (to prospectus dated July 26, 2021) THE BEAUTY HEALTH COMPANY 89,501,743 SHARES OF CLASS A COMMON STOCK 9,333,333 WARRANTS TO PURCHASE SHARES OF CLASS A COMMON STOCK 24,666,666 SHARES OF CLASS A COMMON STOCK UNDERLYING WARRANTS This prospectus supplement is being filed to upd

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 The Beauty Health Company (Exact name of r

Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.4 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the material terms of the securities of The Beauty Health Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). This description of the terms of our stock does not purport to be a complete s

As filed with the Securities and Exchange Commission on March 1, 2022

As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.